Results 161 to 170 of about 74,143 (263)

Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors. [PDF]

open access: yesCancer Res
Krantz S   +11 more
europepmc   +1 more source

High Uric Acid Promotes Stem Leydig Cell Senescence by CCDC90B Mediates Mitochondrial Quality Control Imbalance

open access: yesCell Proliferation, EarlyView.
In hyperuricemia, uric acid inhibits CCDC90B ubiquitination degradation by binding to it. Excessive CCDC90B induces mitochondrial calcium overload, leading to mitochondrial quality control imbalance and ultimately resulting in SLC senescence and decreased testosterone levels.
Jiayu Huang   +8 more
wiley   +1 more source

GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses. [PDF]

open access: yesJ Biomed Res
Wang Y   +13 more
europepmc   +1 more source

Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell‐State Plasticity in the CFTR Modulator Era

open access: yesCell Proliferation, EarlyView.
In cystic fibrosis disorder, CFTR dysfunction drives multilayered intestinal niche disruption, including dysbiosis, inflammation, hypoxia, metabolic stress and genotoxic injury, promoting cell‐state plasticity and a pre‐neoplastic ecosystem. CFTR modulators and environmental factors may partially reshape these processes, highlighting opportunities for ...
Bala Umashankar   +5 more
wiley   +1 more source

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Anti‐PD‐1 response has been associated with higher PD‐1 ligand (PD‐L1) expression levels in different cancer types. Cemiplimab, an anti‐PD‐1 antibody, has been shown to induce a response rate of 31% and 22% in patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC respectively, who have progressed or are ...
Isabella Dommann   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy